SCM Life Science said that it has agreed with MitoImmune Therapeutics to develop a new treatment, which combines clonal mesenchymal stem cells (cMSC) and mitochondria technology.
|SCM Life Science CEO Rhee Byung-gun (left) and MitoImmune Therapeutics CEO Kim Soon-ha signed a business partnership contract at the former's headquarters in Incheon, on Thursday.|
The two companies will carry out the agreement soon to start research into therapeutic agents for intractable, inflammatory, and rare diseases.
"We hope to develop a drug for rare intractable diseases that can enter the global market by combing MitoImmune Therapeutics' mitochondrial control technology and our cMSC technology," SCM Life Science CEO Rhee Byung-gun said.
MitoImmune Therapeutics CEO Kim Soon-ha also said, "Our company expects that its mitochondria platform will provide a differentiated solution for the treatment of rare intractable diseases by modulating mitochondrial functions for SCM Life Science's cMSC."
<© Korea Biomedical Review, All rights reserved.>